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The following case was presented on September 8, 2018 as part of a Clinical-Pathological 
conference chaired by Anna F. Dominiczak and Garry L.R. Jennings at the AHA Council 
on Hypertension | AHA Council on Kidney in Cardiovascular Disease | American Society 
of Hypertension Joint Scientific Sessions 2018 in Chicago, USA. Alan C. Cameron and 
Christian Delles presented the case and led the discussion. 
  
 
 
Case Introduction 
A 73-year-old woman had been monitored in our clinic for a number of years, after being 
diagnosed with essential hypertension in 1994. Her background included hypercholesterolemia, 
hypothyroidism, obesity, and asthma. 
Her anti-hypertensive regimen had included a combination of dihydropyridine calcium channel 
antagonists, fluctuating between amlodipine and lercanidipine over the years, as well as a 
thiazide. She was also taking a statin, a thyroxine replacement, and inhalers. As she had 
previously been troubled by a cough when using an ACE-inhibitor, we avoided that treatment. 
Looking over her trajectory from 2010 to 2013, we can see that she had generally reasonable 
blood pressures (BP) in clinic and at home (Table 1). The key issues were that she developed 
ankle swelling while taking amlodipine in 2012 and was therefore converted to lercanidipine by 
her General Practitioner (GP). In 2012, one slightly elevated clinic reading led to an up-titration 
of lercanidipine. Overall, she had been relatively stable on this regimen. 
I would like to take you on a journey from 2014 to 2018 to look at the changes that occurred 
over that period. If we focus first on 2014, her BP was above target at 152 systolic. At home, 
she was troubled by fatigue, with reasonable BPs.  
Due to fatigue and elevated home readings, her GP changed her lercanidipine to amlodipine. 
Based on the clinic BP, we proceeded to arrange an electrocardiogram (ECG) and an ambulatory 
BP monitor. Her EKG demonstrated sinus rhythm with some ectopics, but not much else. 
  
 
 
Moving on to look at her ambulatory BP in 2014 (Figure 1a), we can see readings that are 
probably reasonable. Although there may be some scope to be more aggressive, there is 
definitely evidence of a loss of nocturnal dips. When we followed up in clinic to review the 
issues, her clinic reading was satisfactory. We therefore continued the regimen, which at that 
time was amlodipine 10 mg and a thiazide diuretic. 
At this point, I think it would be useful to stop the introduction and ask for people's thoughts on 
the case to date and management at that point. What are experts’ opinions? Would anyone 
have done anything differently? 
Discussion 
Dr. Floras: At this point, if I were presented with a hypertensive, obese woman, who 
was reporting daytime fatigue, had developed a peripheral edema after starting a 
dihydropyridine calcium channel antagonist, and had then found that her blood 
pressure did not fall at night, my next step would be to schedule polysomnography. 
Dr. Cameron: This is an excellent point, and we heard discussions yesterday about the 
importance of sleep, hypertension, and cardiovascular risk. In Glasgow, we now have 
much greater focus on that, as well as a specialist clinic. It may be an ideal point to 
consider. 
Dr. Batlle: For a U.S. audience, which may not be familiar with the dosage of this 
diuretic, can you clarify that this is a type of hydrochlorothiazide (because a dose of 2.5 
mg would be totally homeopathic)? In the U.S., we use 12.5 mg of HCTZ as a low dose. 
  
 
 
Dr. Delles: This is a U.K.-specific thiazide. It is like hydrochlorothiazide, and the 2.5 is 
equivalent to the 12.5–25 mg of hydrochlorothiazide. 
Dr. Batlle: Thank you. 
Dr. Bursztyn: I wonder if there is a history of frequent nocturnal urination, which may 
explain her nocturnal hypertension on a behavioral, rather than physiological, basis. 
Dr. Cameron: Again, that is an interesting point. Perhaps it is a question we do not ask 
often enough in clinics and something that we should probe more deeply—an excellent 
point for discussion. 
 
Follow-up of hypertensive patients 
These were some of the issues we considered. We did wonder whether the ambulatory 
monitors that we had arranged provided enough useful information. We saw the loss of the 
nocturnal dip. Should we have made an adjustment at that point on the basis of the patient’s 
current BP? We have touched upon the thiazide, which is slightly unusual but a common 
treatment in the U.K. 
Is bendroflumethiazide, which is predominantly a U.K. drug, the most appropriate thiazide we 
can use, or do other agents act better? Particularly if someone is stable, should we change the 
treatment or continue on the current regimen? A key issue to discuss is the follow-up on this 
lady. We have seen that she is relatively stable, but with a loss of nocturnal dip. How frequently 
  
 
 
should we follow up on her? What is the best setting to do that in, and what approaches should 
we take? I will hand over the discussion to Dr Delles and he will talk through those questions. 
Thanks very much. There is not that much to discuss, because you have mentioned some of 
these issues; they are part of the reason why we wanted to present this case. Back in 2014, this 
was a very stable patient who had attended the clinic for quite a few years. I think our clinic is 
as busy as many of yours, so the question really is whether management would change 
dramatically if there were 15 or 20 patients on the list and some of them were presenting with 
real issues. And then you had this one, who was not actually too bad. Her blood pressure was 
okay; she was complaining of some fatigue but had no real red-flags. I think it was perfectly fine 
management, at this point in time, to say, “We are not making any major changes here.” 
However, I take the point that sleep studies and other approaches might be appropriate, 
especially now in 2018. 
What I want to show very briefly comes from the new guidelines: the actual recommended 
follow-up (Figure 2)1. I think you are all aware that, at the very beginning of managing 
hypertensive patients, we should be much more aggressive with the follow-up and see patients 
more frequently—at approximately monthly intervals. 
Later on, three- to six-month intervals are entirely appropriate. These follow-up appointments 
should focus on adherence and a number of other issues, including side effects, but should also 
include occasional screenings for other conditions, such as target-organ damage. Of course, we 
should always bear in mind that somebody who is labeled primary or essential hypertensive 
  
 
 
could, after many years, still develop a secondary form of hypertension, and we should always 
be alert to this. 
One of the issues that Alan has kindly pointed out was the loss of nocturnal dip, which is 
something we can discuss later on during the presentation. Would this be a symptom that 
would trigger a search or investigation into secondary forms of hypertension, which could be 
associated with this finding? 
There may be a few situations wherein we should screen for secondary hypertension, and the 
loss of nocturnal dip in this patient is one factor that could have triggered further 
investigations. It was not discussed very much, back in 2014, because everybody was so happy 
that she was well controlled. 
Taking you now to 2015, she presented to her GP complaining of predominantly atypical chest 
discomfort, with no other associated symptoms, and was referred to a cardiology clinic. Her BP 
was elevated at 160/80 mmHg, but the cardiology examination was otherwise unremarkable. 
The cardiologists proceeded initially with an ECG, which was generally unchanged. An exercise-
tolerance test was carried out; likely due to her body habitus, she could only exercise for three 
minutes out of a predicted six. Overall, it was a relatively satisfactory exercise-tolerance test. 
These results, combined with her atypical symptoms, reassured the cardiologists that her 
symptoms overall were not suggestive of ischemia. They noticed the elevated clinic BP, which 
contrasted with earlier results, and arranged an ambulatory BP monitor and echocardiogram. 
  
 
 
We will look at the echocardiogram images first. Essentially, what we see is mild concentric left 
ventricular hypertrophy (Figure 3a). If we were able to show all of the images, we would see 
that the LV function was satisfactory. Overall, there was some mild concentric LVH. 
As I mentioned, they also arranged an ambulatory BP monitor (Figure 1b). We can see a marked 
difference compared to previous results, with readings averaging up to around 190 mmHg 
systolic, and the continuing loss of nocturnal dip. This was certainly more elevated than her 
clinic BP at that point. 
On the basis of these results, I wondered what you thought of this case and what steps you 
would take next to manage it. She was then on amlodipine 10 mg and bendroflumethiazide 2.5 
mg.  
Discussion 
 
Dr. Taler: I was going to say before this last part that I think it was probably not 
appropriate to ignore her ambulatory monitor and withhold drug treatment because 
her office reading was acceptable. I think that you left the door open for ongoing target-
organ damage by doing that. This second monitor result is very different and her 
pressures are quite high now, so I think it is appropriate to look for a secondary cause, 
as well as assess target-organ damage. I would say there is a nocturnal fall in there, 
maybe not a full 20%, but that is not my major concern. I am more worried about her 
inadequate blood-pressure control. 
  
 
 
Dr. Cameron: Exactly. That is one of the points that we hoped to tease out of this 
discussion. Was it a missed opportunity, based on the previous ambulatory monitor? 
We were reassured when she followed that up with a clinic BP, which we felt was 
satisfactory, but was there an element of masked hypertension? We have discussed this 
question over the past few days at the conference, as something that we need to be 
much more aware of and more aggressive in our management of. 
Dr. Chugh: As we are trying to treat the hypertension, we are also trying to figure out 
what else is going on with this patient, and the one thing that keeps coming up is that 
the patient is fatigued. I still do not have a clear idea of the etiology of that, but I do not 
think it is simply a result of not sleeping well. The issue is with the echo—what was the 
diastolic function there? Did you get any numbers? For example, was there an elevated 
right atrial pressure? What were the PA pressures? 
Dr. Cameron: I do not have that data, unfortunately, but the cardiologists were certainly 
reassured about her systolic function. Whether there was any element of diastolic 
dysfunction— I think that is certainly possible. Although I do not have the indices to 
discuss that with you, it is an important area to consider. One excellent point to 
establish is whether there was an element of diastolic dysfunction, perhaps even 
progressing to symptoms of heart failure with preserved ejection fraction (HFpEF). 
Dr. Chugh: That would lead me to be slightly more aggressive with my diuretics in this 
situation. Was there anything in the examination, like a jugular venous dilatation (JVD) 
or edema? Did you see any sort of signal there? 
  
 
 
Dr. Cameron: No, the examination was unremarkable. But one of the points that will 
come up as we go through the presentation is the fact that she complained of a swollen 
ankle, which is often attributed to amlodipine. Should we be more inquisitive when 
patients present with swollen ankles? Did we, perhaps inappropriately, attribute that 
symptom to her amlodipine—and should we have thought more about HFpEF or 
considered diuretic up-titration? 
Dr. Chugh: If I recall correctly, your EKG may have reached the criteria for LVH, based on 
the Cornell Criteria. She met 20 with the V3 and aVL. 
Dr. Cameron: Yes, thank you. 
Dr. Batlle: You present good documentation of the progression or worsening of her 
hypertension over time. Often, we simply do not know that relatively rapid progression/ 
worsening has occurred. In this case, the differential diagnosis, given the age of the 
patient, would include the first renal artery stenosis. We need information on urine 
protein, because proteinuria is often a sign of unilateral renal artery stenosis. In other 
words, de novo proteinuria may be a sign of angiotensin II-dependent hypertension. Can 
you share this information? 
Dr. Cameron: She did not have proteinuria. We did not reevaluate the ultrasound 
imaging. As Christian asked earlier, when we see these patients and note a change over 
time, should we go back to the start? She had been monitored for many years in the 
clinic and things seemed fairly stable until the small change in 2015. Should we have 
  
 
 
gone back to the drawing board and started her evaluatory workup again? This is an 
important point. 
Dr. Batlle: Well, will you tell us… 
Dr. Cameron: We have not proceeded to the renal ultrasound, so I do not have that 
information, but she does not have proteinuria. 
Dr. Batlle: Very good, thank you. 
Prof. Bursztyn: I wonder about the decisions about chronic drug management. Of 
course, we would all sympathize with not changing a successful or apparently successful 
treatment. On the other hand, as every treating physician is well aware, if a patient has 
obstructive cardiomyopathy, dihydropyridines are usually inappropriate. Diuretics 
would not be recommended in this case because they can exacerbate obstruction. For 
these reasons, I am not all that surprised that she became symptomatic. 
Prof. Bursztyn: Moreover, if you had to treat her with calcium channel blockers, high-
dose verapamil would probably have been more appropriate. What was her ACE-
inhibitor intolerance? How did it manifest? Was it a cough or hypotension? 
Dr. Cameron: It was cough a number of years ago. You touch upon a very interesting 
point with verapamil that we will come back to later in the presentation.  
Prof. Bursztyn: So, obviously, the alternative might have been useful. 
  
 
 
Dr. Cameron: Exactly, yes. 
Dr. Floras: We do not seem to have demonstrated left ventricular outflow-tract 
obstruction yet, so I think Dr. Bursztyn is ahead of us. 
Dr. Cameron: Exactly, yes.  
Dr. Floras: Looking at that echo, which does not demonstrate left ventricular outflow-
tract obstruction, and considering the potential causes of exertional chest pain, in a 
hypertensive woman with a low pre-test probability of coronary artery disease, I would 
often recommend treadmill stress echocardiography to document estimated right 
ventricular systolic pressure before and at the end of exercise. In our clinical experience, 
the chest pain these women describe is due to high pulmonary artery pressure induced 
by exercise, rather than coronary artery disease. It can be attenuated by lowering 
exercise blood pressure. 
Dr. Floras: The other practical point is that, when a patient develops a gravitational 
edema with drugs like amlodipine, this fluid will shift over the course of the night. Our 
research has shown that this fluid will shift overnight to the chest and up into the neck. 
This leads to an increase in neck diameter, a reduction in upper-airway caliber, and an 
increase in upper-airway resistance. The more fluid shifts rostral, the greater the apnea-
hypopnea index. I would therefore propose that, in this woman, the edema, nocturia, 
and fatigue were all signs of obstructive sleep apnea. 
  
 
 
Dr. Cameron: Yes, excellent points are coming out in terms of the exercise-tolerance 
test. Perhaps we should have proceeded to stress imaging, and yes, we have already 
touched on sleep earlier in the morning. So, exactly, ideal points are coming out. 
 
Masked hypertension 
I will move on, in the interests of time. We have touched upon these issues. The overall 
impression was of masked hypertension. The etiology of her chest pain—should we have 
carried out more detailed investigations of that? Not necessarily for obstructive coronary artery 
disease, but for other factors that contribute to chest pain. 
In terms of the management, we added an angiotensin receptor blocker (ARB), commencing 
Losartan 50 mg at that point. We have considered whether this lady may have had masked 
hypertension. We saw evidence of it earlier that perhaps was not fully understood or acted 
upon. We are certainly more convinced by the ambulatory monitor that we have now seen. 
This topic will come up again over the course of the conference. It is a common condition in our 
patients, with prevalence of up to 30%, and it is not a benign phenomenon. 
Here, I present data on the prevalence of cardiovascular events, comparing normotensive and 
masked hypertensive patients; there is a two-fold increase.2,3 In terms of cardiovascular 
mortality and the risk of stroke, the prevalence is comparable to that of patients with sustained 
hypertension, so it is not a condition to ignore. We need to be more aware of this condition and 
to act more aggressively when we see it. In terms of detection and management, the 2017 
  
 
 
guidelines state that if we have patients with office BP at goal, whom we feel are at increased 
cardiovascular risk—or if we have evidence of target-organ damage—then we should screen 
them for masked hypertension and intensify treatment strategies if any is detected1. 
Moving on to 2016, the patient in question complained of further symptoms that might be 
considered nebulous, but could also be more significant: postural exertional lightheadedness 
and ankle swelling, which was a recurring theme. Her clinic and home BP readings were 143 
and 135 systolic. The ankle swelling was perhaps inappropriately disregarded, due to the 
dihydropyridine. We reduced the dihydropyridine to 5 mg, up-titrated the Losartan, and 
continued the thiazide. Overall, her symptoms did improve slightly with that approach and her 
BP was around 140/90 both in clinic and at home. 
Things took a fairly marked turn in 2017. She had been seeing her GP for a couple of weeks, 
with increasing dyspnea, fatigue, and peripheral edema. The GP felt that this was due to her 
dihydropyridine and converted the amlodipine to lercanidipine. She also had symptoms of a 
lower-respiratory infection with a cough, productive of a small amount of green sputum. Her 
BP, in contrast to earlier readings, was markedly reduced, at 106 systolic. She had a relative 
tachycardia, with a heart rate of 90, which had been much lower previously. She had a loud 
systolic murmur audible across the precordium with bi-basal crepitations and mild pedal 
edema. 
Her ECG changed at that point. We have questioned whether the previous ECG showed 
features of LVH and I think there is LVH here. It also looks more tachycardic than before. 
  
 
 
We arranged a chest X-ray to look for consolidation or any frank pulmonary edema. You can see 
that the cardiac size was increased. However, there was no frank edema and certainly no 
consolidation. 
This is a more interesting echocardiogram image. We can see that there is much more 
impressive left ventricular hypertrophy—severe left ventricular hypertrophy on this apical four-
chamber view (Figure 3b). If we move through to the parasternal short axis (Figure 3c), we can 
see much more marked left ventricular hypertrophy, concentric in nature. 
Going back now to the four chambers, a key feature of the left ventricular outflow tract is the 
motion of the mitral valve. Systolic anterior motion, combined with a really chunky septum, 
narrows the left ventricular outflow tract and markedly impairs cardiac output. This represents 
a real change in the echocardiogram findings, compared to what we saw previously. 
We note severe left ventricular hypertrophy, left ventricular outflow-tract obstruction (LVOT), 
and systolic anterior motion of the mitral valve. Importantly, we have considered whether this 
patient might have had masked hypertension, perhaps against a background of essential 
hypertension with a loss of nocturnal dip. 
At this point, I would like to open this up for discussion. Given these echocardiogram findings 
and the patient’s symptoms at this point, what are your thoughts? Do you agree with our 
impression so far? How would you move forward? Any suggestions? 
Discussion 
  
 
 
Dr. Chugh: Given that the cavity is so small, with a true LVOT obstruction, I would 
certainly think about a beta blockade in a situation like this, to try to get that heart to 
really slow down, give it some more filling time, and relieve that LVOT obstruction. 
Dr. Chugh: By increasing the amlodipine, the GP essentially increased the gradient 
across the LVOT and accentuated the LVOT obstruction. So now, we should back off the 
dihydropyridine and really allow that LVOT to open up through all phases of systole. 
Could you just review the BMI of the patient one more time? 
 
Dr. Cameron: In the region of 30. 
Dr. Chugh: Okay, so a little bit on the chunkier side. Is she a small woman? 
Dr. Cameron: About five foot, seven inches. 
Dr. Chugh: So she is a larger woman. One challenge that we face involves women of 
smaller stature, who have small LVs to begin with. If their weight increases over time, 
what you have is a very small heart attached to a large body, which obviously 
exacerbates the low-output state. To those patients I would certainly want to say, "It is 
time to really start dialing down the pounds.” That would be something to think about 
because it would go a long way here as well. 
Dr. Jennings: We have two suggestions, a beta-blocker or verapamil. Which did you 
choose? 
 
  
 
 
Dr. Delles: She got amlodipine and losartan. I agree that the amlodipine was not good 
for the gradient. The other drug introduced against the background of the mild LVH was 
the losartan, which had exactly the same effect, further increasing the gradient. Alan 
will discuss some of the details, how this patient’s clinical decompensation was 
triggered by some of the measures taken, as well as by other precipitating factors. 
 
Left ventricular outflow-tract obstruction 
To review what we did at that point, perhaps not ideally, we stopped losartan, withheld 
bendroflumethiazide, and continued the dihydropyridine. On reflection, was that the most 
appropriate approach? Probably not. We will discuss the left ventricular outflow-tract 
obstruction, which often creates an impression of heart failure; traditional approaches to 
management can actually be deleterious. Specifically, initial management strategies for patients 
who appear to have heart failure can be deleterious if the patients have left ventricular 
outflow-tract obstruction. 
We arranged an ambulatory monitor (Figure 1c) and an urgent referral to colleagues in the 
cardiology department. I will not dwell on the ambulatory monitor, but it looks more consistent 
with previous, more reasonable readings. The key point is that we managed to start some 
calcium channel antagonists, with verapamil, initially 40 mg three times a day, up-titrating to a 
more reasonable sustained release. We restarted the diuretic and discontinued lercanidipine. 
  
 
 
Left ventricular outflow-tract obstruction is a key issue.4,5 It is something we should be more 
aware of and should certainly screen for more often. The condition requires an anatomical 
substrate, as well as a physiological trigger (Figure 4a). Hypertension and aortic stenosis often 
lead to an increased afterload. Perhaps in the case of this patient, an element of masked 
hypertension led to left ventricular hypertrophy and some diastolic dysfunction. 
With left ventricular outflow-tract obstruction, as well as the anatomical substrate, there is 
some form of physical trigger, which can either be a physiological response, perhaps to sepsis, 
with relative hypotension in this case, or vasodilators. These accentuate the problem, leading to 
impaired diastolic filling, left ventricular outflow-tract obstruction, and near obliteration of the 
LV cavity. The systolic anterior motion of the mitral valve, which then occurs, really narrows the 
left ventricular outflow tract and leads to the typical triad of symptoms: chest pain, 
breathlessness, and syncope. 
To manage the condition most effectively, we need to avoid treatments such as vasodilators or 
positive inotropes that may be introduced if clinicians adopt the wrong strategy and fail to 
screen fully for LV outflow-tract obstruction. We need to think about beta-blockers or calcium 
channel blockers (Figure 4b). In this case, we chose a calcium channel blocker, verapamil, with 
subsequent up-titration. These agents improve the diastolic filling while slowing down the heart 
rate. They allow some reduction in the LV outflow tract, reduction of the systolic anterior 
motion, and improvement of symptoms. That is the approach we took with this lady. 
If we fast-forward to 2018, her exercise tolerance improved; although her BP did not reach the 
ideal target, it was maintained on verapamil. At this point, because her symptoms and exercise 
  
 
 
tolerance had improved, we felt that we could re-add an ARB, continue bendroflumethiazide, 
and achieve more satisfactory BP readings at home and in the clinic. 
We updated her ambulatory monitor just a week or so ago, and can see much more satisfactory 
readings, again with the loss of the nocturnal dip (Figure 1d). 
If we compare the echocardiogram after that period of management with verapamil, we can 
see marked improvement in the left ventricular hypertrophy, and a much more open left 
ventricular outflow tract, which has  contributed to the marked improvement in symptoms 
(Figure 3d). 
We have now taken you on a journey that began in 2014, when a lady who had been relatively 
stable developed masked hypertension and a loss of nocturnal dip. She began to develop 
severe left ventricular hypertrophy, probably due to the masked hypertension. When we first 
detected the masked hypertension, we were not as aggressive in our management strategies as 
we could have been. Perhaps we could have prevented the progression to the anatomical 
substrate that, combined with the physiological trigger of relative hypotension in the context of 
an infection and various management strategies, may have contributed to left ventricular 
outflow-tract obstruction. 
It is a condition to be aware of because the management implications are really important. If 
you adopt strategies that would be appropriate for heart failure (using diuretics in the first 
instance) without considering a beta blockade or a rate-limiting calcium channel blockade, then 
you may be going down the wrong path. You will exacerbate the symptoms and make the 
  
 
 
situation worse.  Reports from case presentations in the late 1980s have described this 
progression. 
Fortunately, we were able to identify this patient’s masked hypertension and to treat her 
relatively promptly with a negative inotrope that led to marked improvement in her symptoms 
and echocardiogram findings. 
I hope that we have discussed some key features of masked hypertension, which is not a benign 
phenomenon. We have talked about the importance of considering and probing natriuresis at 
night and examining sleep studies. We have considered the use of more appropriate imaging to 
examine the symptoms of chest pain, perhaps with some functional imaging, and the 
management of left ventricular outflow-tract obstruction to improve symptoms. 
I would like to thank everyone for their attention and contributions. As we still have time, we 
will open up the floor for discussion again. 
Discussion 
Dr. Jennings: Thank you. I have a comment and a question. Firstly, I would have 
expected her to improve with the treatment you gave her, but her response, especially 
with the echo, was miraculous. 
Dr. Jennings: Secondly, many people have longstanding hypertension and do not follow 
this path. I wonder whether this lady has late-onset hypertrophic cardiomyopathy and 
  
 
 
whether you've looked at her sarcomeric genes, particularly myosin binding protein C, 
which is often behind that. 
Dr. Cameron: Sure. That is an important point. Is this just simple LVH due to 
hypertension, or could there be a more familial component? Because of its more 
concentric nature, it was considered more likely to be hypertensive, although a 
hypertrophic obstructive cardiomyopathy (HOCM) picture was not excluded. Given the 
improved echocardiogram findings, along with her symptoms, we have continued down 
that route. However, it would have been something to consider, had she not continued 
to improve. Should we look at these proteins or even consider MR imaging for a more 
detailed evaluation? 
Dr. Cameron: Yes, it is important to be aware we do not attribute this fully to 
hypertensive LVH; we remain aware that a familial component is possible. 
Dr. Jennings: Both in athletes and in hypertension, there is hemodynamic stress, but it 
manifests against a background of the underlying genetic or constitutional makeup. 
Clearly, this lady was much more prone to hypertrophy than most people.  
Prof. Bursztyn: I would like to comment exactly on this point. My cardiology associates 
would probably have said that this was hypertrophic cardiomyopathy, with 
hypertension on the side. At the same time, it would actually be a bit obscene to call it 
familial hypertrophic cardiomyopathy, especially in a patient with hypertension or 
severe hypertension. I would like to add a clinical perspective. As clinicians, we ought to 
  
 
 
seek treatable diseases. Since hypertrophic cardiomyopathy can improve 
symptomatically, as demonstrated here, while being false, hypertensive heart disease 
should be given higher consideration because it is preventable and, at least to a certain 
extent, reversible. 
Dr. Cameron: Yes, thank you. 
Dr. Tifft: Was there much discussion about the dose of verapamil? You jumped to the 
other drugs fairly readily. What about using higher doses, as high as 540 mg, which 
some people use in this kind of situation? You have treated the blood pressure 
beautifully, but, given that you are trying to understand what the problem is, why not 
use more verapamil?  
Dr. Cameron: Yes, that is an interesting point. I guess we began by being a little too 
cautious. Perhaps caution is a recurring theme in this case. We could certainly have 
considered higher doses.  
Dr. Tifft: Was it the fact that you had crackles or something similar? I do not think they 
would bother me particularly in this situation.  
Dr. Cameron: The dosage was guided by our cardiology colleagues, rather than 
ourselves, so I do not have the background to explain why they stopped with that dose. 
However, it is a theme that we could have been more aggressive throughout the case. 
  
 
 
Dr. Delles: At the same time, the other vasodilators were stopped; some drugs that 
were negatively influencing the gradient were stopped, and the patient received some 
verapamil on top of this. So she did benefit from two therapeutic approaches at the 
same time. However, I agree that the verapamil could have been higher. 
Dr. Mihailidou: Initially, the loss of nocturnal dip is an important trigger, particularly in 
women. Many years ago, there was a study, which showed that a lack of nocturnal dip 
in females (it was not called masked hypertension in those days) led to hypertrophy. So 
we need to be aware that an initial ambulatory monitor is essential. The other factor is 
that masked hypertension can only be diagnosed by an ambulatory monitor—there is 
no other way to diagnose it. We have had many discussions about the lack of 
reimbursement, particularly in America, which impedes ambulatory monitoring. Perhaps 
that is something to take up with the associations, because this condition is not benign. 
Dr. Delles: I could not agree more. This lady probably had three or four ambulatory 
readings over the whole period of time, which is not too bad. However the discrepancy 
between clinic readings that are generally fine, but occasionally high, was confusing; the 
usual inertia may have led to the view that stress at home or other factors caused this 
condition. We have ambulatory readings as proper 24-hour readings, and we also have 
home BP readings. 
Dr. Delles: I think what we all do, as this case highlights, is to pick the best readings and 
take the ones we like most and we say, well despite the absence of a dip, most of her 
home readings are fine, so we should not increase the treatment. You have pointed out 
  
 
 
very rightly that the absence of dip and the slightly borderline blood pressure were 
observed in 2014 and should have triggered a more aggressive treatment. 
Dr. Mihailidou: She still lacks a nocturnal dip. What are you doing for that? 
Dr. Delles: That is quite right. We are happy to take your advice. 
Dr. Batlle: I think this case should be characterized as a case of severe progressive 
hypertension. Masked hypertension is a term that should really be reserved for patients 
who have normal or close to normal blood pressure in the office, but much higher blood 
pressure at home with associated target damage. The high BP documented by ABPM is 
consistent with masked hypertension but the office BP readings are actually more 
variable in this case. 
Dr. Batlle: I think this could be described as a case of progressive severe hypertension, 
rather than masked hypertension, although an element of masked hypertension could 
be emphasized. The lack of dip in this hypertensive patient is another sign of severe 
hypertension, according to the definition. You never told us what the follow-up was. 
Was the patient’s blood pressure markedly improved after the verapamil, or did it 
merely improve her symptoms without fully controlling her blood pressure? I suspect 
that this is a case of severe hypertension and you need to add spironolactone or 
something else to control the blood pressure. What happened to her blood pressure at 
the end? 
  
 
 
Dr. Delles: The last ABPM reading from a week ago showed much better blood-pressure 
control; however, it was still not quite in the optimal range and there was still a loss of 
nocturnal dip, so she may benefit from some changes in her treatment. Spironolactone 
is actually an interesting idea, especially given her history of left ventricular 
hypertrophy. 
Dr. Peixoto: I think you have three sequential comments related to that. You have a 
wealth of information about her nocturnal pressure, but limited steps were taken, from 
both an investigative and management standpoint. I would argue that spironolactone 
would not only have added value in terms of overall blood pressure measurement, but 
also in relation to our discussion  about rostral shifts, fluid shifts. If the patient is obese 
with a little excess aldosterone or sleep apnea (which should be investigated, as others 
have said), spironolactone could have a favorable effect. Now that her LVOT obstruction 
is gone or significantly improved, any diuretics could be used safely. If we believe in the 
value of spironolactone in HFpEF, it could have a double effect. 
Dr. Bittman: I was going to ask about the role for spironolactone, so, thank you. I did 
want to raise one question about keeping the term "masked hypertension." While I 
agree that blood pressures should be defined as normal in clinic, one problem in this 
case was that we did not highlight the home blood pressures enough. Removing this 
term from the diagnosis or label could suggest that the patient should be tested only in 
the office. It is important to emphasize the need to use home blood pressures for this 
patient. I do not know how these considerations balance out. 
  
 
 
Dr. Delles: One key point is that we really need to look at this patient’s ambulatory 
profile. To come back to the term, “masked hypertension,” you have seen the very bold 
statement in the presentation title and may also have seen Alan's small question mark 
on one of the slides, where he asks, “is this actually masked hypertension?” As this 
discussion has shown, it is defined as masked hypertension because we picked the one 
time point where there was a clear discrepancy between clinic blood pressure and 
ambulatory readings. Could this really be a case of discordant blood pressure readings 
over time? They occur in many patients. We may have just missed a natural progression 
of hypertension, indicated by a number of readings over time. 
Dr. Chugh: In defense of cardiologists, I will tell you that we would not necessarily have 
called this patient HOCM, simply because there is such a terrible association with 
sudden cardiac death. Before we start telling patients that they are at higher risk for 
sudden cardiac death, we would want to do a bit of investigation. This may be a 
shameless plug for cardiac MRI, because it is my specialty, but in situations where you 
see a precipitous increase in the LV mass, as we saw in this case, a cardiac MRI would be 
helpful from both a diagnostic standpoint (to see if the patient has late-onset HOCM) 
and a prognostic standpoint. If you see a lot of fibrosis in the LV myocardium, then you 
know there is a higher risk of ventricular arrhythmias. The way you treat that patient will 
be different than if you had seen a low burden of fibrosis. Fibrosis can happen, not only 
in HOCM, but also in hypertrophic remodeling from hypertension, aortic stenosis, and a 
myriad of clinical issues. 
  
 
 
Dr. Chugh: The last point I would make is this. If you notice, this patient already has left 
atrial enlargement on the echo, so she is knocking on the door of atrial fibrillation, and 
she does have some palpitations. 
Dr. Cameron: Thank you; we know what to do when those occur. 
Dr. Delles: Okay. So, this is a patient who did not look too bad in 2014. Clinics are 
obviously under a lot of pressure to discharge patients from specialty follow-up. If we 
had done so at the time, leaving the patient to be seen by a GP, we might have missed 
even more opportunities. 
Dr. Delles: Unfortunately, what we did was probably not much better. This is one of the 
reasons why we picked this case. Even with specialist management, we were not quite 
on the right track. We really must make sure that our specialist services deliver what 
they promise and that we take these patients and their symptoms very, very seriously. 
This discussion has revealed a number of moments when we could have taken a slightly 
different route. 
Dr. Taler: I think this goes back to guidelines and targets—the higher we set the target, 
the more cases will pass through. If our primary care providers had used a target of less 
than 150 systolic, this lady would have been controlled. Instead, she developed 
hypertensive heart disease. If we had used the European guidelines, I think this lady 
would have been almost controlled. Moreover, there is a creep there. Well, she is close 
to the target; I do not want to hurt her; I do not want her to fall down or pass out; and 
  
 
 
so we under-treat people. This is an educated, adherent woman, who takes her 
medication, and yet in front of our eyes, your eyes, she developed hypertensive heart 
disease. She should not have developed that. I think when we start ratcheting up the 
targets because we are worried, we serve the patient poorly. 
Dr. Jennings: I think at this point we will stop. We have had a wonderful discussion and 
there is much to reflect on. It is interesting that this rather unusual case has implications 
for the general run of hypertensives that we treat. 
Dr. Jennings: Thank you both, Alan and Christian. 
 
Summary 
Masked hypertension is not a benign phenomenon and regular ABPM should be 
considered in patients with masked hypertension to maintain aggressive BP control and 
prevent target-organ damage. Left ventricular outflow-tract obstruction should be 
managed with negative inotropes such as beta-blockers, or rate-limiting calcium channel 
blockers; vasodilators and positive inotropic drugs should be avoided. 
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Figures 
Figure 1 
Ambulatory blood pressure monitors from:  
(a) 2014 
(b) 2015 
(c) 2017 
(d) 2018 
 
Figure 2 
2017 American Heart Association guidelines for the follow-up of patients with 
hypertension 
 
Figure 3 
Echocardiogram images from: 
(a) 2015, mild concentric left ventricular hypertrophy 
(b-c) 2017, severe left ventricular hypertrophy with left ventricular outflow-tract 
obstruction 
(d) 2018, mild concentric left ventricular hypertrophy 
 
Figure 4 
Left ventricular outflow-tract obstruction: 
(a) Pathophysiology 
(b) Management  
  
 
 
 
  
 
 
Tables 
 
Table 1 
Clinical trajectory from 2010 to 2013 
 
Year 
BP 
(mmHg) 
Clinic / 
Home 
Issues Regimen 
2010 
132/80 
134/81 
Clinic Nil 
Amlodipine 10 mg 
Bendroflumethiazide 
2.5 mg 
2010  130/80 Home Nil 
2011 122/80 Clinic 
Personal issues 
Fatigue 
2012 120/78 Clinic Ankle swelling 
Lercanidipine 10 mg 
Bendroflumethiazide 
2.5 mg 
2012 157/86 Clinic Home stress Lercanidipine 20 mg 
Bendroflumethiazide 
2.5 mg 
2013 141/77 Clinic Nil 
2013 116/68 Clinic Nil 
  
 
 
 
